Erik Duijvelaar

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Angiotensin Converting Enzyme

Chronic Myeloid Leukemia

Placebo Controlled

Top Venues

Critical care (London, England)

Nature communications

The European respiratory journal

This page only lists publications with an associated author ORCID identifier.

Publications

Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Erik Duijvelaar, Jack S Gisby, James E Peters, Harm Jan Bogaard, Jurjan Aman
Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients. Nature communications 15 (1) (2024)
Erik Duijvelaar, Jack S Gisby, James E Peters, Harm Jan Bogaard, Jurjan Aman
Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients. Nature communications 15 (1) (2024)
Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Erik Duijvelaar, Jack S Gisby, James E Peters, Harm Jan Bogaard, Jurjan Aman
Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients. Nature communications 15 (1) (2024)
Erik Duijvelaar, Xiaoke Pan, Harm Jan Bogaard, Etto C Eringa, Jurjan Aman
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Critical care (London, England) 28 (1) (2024)
Justin de Brabander, Erik Duijvelaar, Job R Schippers, Patrick J Smeele, Hessel Peters Sengers, Jan Willem Duitman, Jurjan Aman, Harm J Bogaard, Tom van der Poll, Lieuwe D J Bos, null null
Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. The European respiratory journal (2022)